Take the Chronic Pain In America Survey! (Now Closed)We know the frustrations of chronic pain. Will you help others understand by taking our survey? Simply put, living with chronic pain is painful. But there is so much more... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
FDA Approves Rozlytrek (entrectinib)As more research is being done on cancer and its treatments, more targeted treatments are becoming available, particularly biologic drugs. The drug Rozlytrek (entrectinib) was approved by the Food and... By Editorial TeamBookmark for later Reactions 0 reactions Comments1 comments
NCI Annual Report Shows Cancer Mortality Rates Continue to DeclineEvery year, there is an annual report to the nation about cancer: rates of occurrence, mortality, and various trends in oncology. It is jointly issued by the Centers for Disease... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
Project Facilitate to Increase Access to Compassionate Use TreatmentsFor some battling cancer, especially those with more advanced or aggressive cancers, approved or available treatment options may eventually become limited. When this happens, some may turn to clinical trials... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
Using AI in Lung Cancer ScreeningA team of Google engineers teamed up with researchers at Northwestern University Feinberg School of Medicine to create a computer program that spotted lung cancer more accurately than expert radiologists... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
Zirabev, Avastin Biosimilar, Approved by FDAThe United States Food and Drug Administration (US FDA) announced its approval of Zirabev, a biosimilar to Avastin. Zirabev (bevacizumab-bvzr) is made by Pfizer and is approved for the treatment... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
FDA Approves Keytruda for Metastatic Small Cell Lung CancerThis week, the United States Food and Drug Administration (FDA) approved the use of Keytruda (pembrolizumab) for the treatment of metastatic small cell lung cancer (SCLC). This is an exciting... By Editorial TeamBookmark for later Reactions 0 reactions Comments11 comments
Take The Clinical Trial Patient Voice Survey (Now Closed)Have you participated in a clinical trial? Are you interested in participating in future clinical trials? We want to hear more about your experience! LungCancer.net/Health Union is teaming up with... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
FDA Expands Use of Keytruda for Treatment of NSCLC (TPS ≥ 1%)This past week, the US FDA (the United States Food and Drug Administration) expanded the use of the cancer immunotherapy drug Keytruda (pembrolizumab). Keytruda is indicated for use by individuals... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
Atezolizumab (Tecentriq) Receives FDA Approval for Extensive-Stage Small Cell Lung CancerThis week, the United States Food and Drug Administration (FDA) approved the use of atezolizumab (Tecentriq) for the initial treatment of extensive-stage small cell lung cancer (ES-SCLC) in addition to... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
Death Rates from Cancer Continue to Fall in the USDeath rates from common cancers have continued a 25-year decline throughout the United States. From 1991-2016, the overall death rate from cancer declined 27%, resulting in an estimated 2.6 million... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
Research Shows Cancer Likely to Become More Deadly than Heart DiseaseHeart disease is the leading cause of death in Americans, but new research shows that cancer is likely to surpass heart disease as the number one killer in 2020, especially... By Emily DownwardBookmark for later Reactions 0 reactions Comments1 comments
FDA Approves Vitrakvi as New Oncology DrugOn Monday, November 26th, 2018, the U.S. Food and Drug Administration (FDA) announced the approval of a new oncology medication, Vitrakvi (larotrectinib). This drug is the second approved medication in... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
FDA Approves Lorbrena for ALK+ NSCLCThe U.S. Food and Drug Administration (FDA) has granted an accelerated approval for Lorbrena (lorlatinib) in the treatment for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who have... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
LungCancer.net is on InstagramDid you know that you can find the LungCancer.net community on Instagram? We're excited to be sharing the same great information (plus extras!) on living with and caring for loved... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
How's Your Relationship with Your Doctor? Take our Survey! (Closed)Do you feel heard by your doctor? Do your questions get answered? We want to hear from you! We’re conducting a survey to learn more about your relationship with your... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
Take the Impact of Cancer Survey!Managing life with cancer can be incredibly difficult. While some treatments and side effects have become common knowledge, there is so much more about life after a cancer diagnosis that... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
Higher Rates of Lung Cancer in Young Women UnexplainedNew research shows that lung cancer rates are increasing among young women in the United States and researchers aren’t sure why. In fact, a new study found rates of lung... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
Take the Clinical Trial Patient Experience Survey!Have you participated in a clinical trial? We want to hear more about your experience! We are conducting a short survey to understand how patients are involved in the clinical... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
New Look, Same Great Community!You might notice a few changes in the way things look when you visit LungCancer.net. Never fear! You still have the same tools for finding info and connecting with others... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
